Gilead Sciences, Inc.
333 Lakeside Drive
Tel: 800-GILEAD-5 or 650-574-3000
About Gilead Sciences, Inc.
Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need.The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
CEO: John F. Milligan, PhD
Chief Scientific Officer: Norbert W. Bischofberger, PhD
CFO: Robin L. Washington
COO: Kevin Young
Please click here for clinical trial information.
1430 articles with Gilead Sciences, Inc.
Agenus Inc announced that the FDA has accepted the company's IND filing for AGEN1423 - a milestone in its partnership with Gilead Sciences, Inc.
Gilead Announces Data From Two Studies Supporting Further Development of GS-6207, a Novel, Investigational HIV-1 Capsid Inhibitor as a Component of Future Long-Acting HIV Therapies
Gilead Sciences, Inc. announced findings from two studies that support the further development of GS-6207, a novel, selective, first-in-class inhibitor of HIV-1 capsid function, for potential future use as part of long-acting HIV combination therapy.
Gilead Presents New Data on Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) and TAF-Based Regimens for the Treatment of HIV-1 in Children, Older Adults and Women
Gilead Sciences, Inc. announced 48-week results from a Phase 2/3 study evaluating the efficacy and safety of Biktarvy®, a once-daily single tablet regimen, in virologically suppressed adolescents and children at least 6 years of age who are living with HIV.
Gilead Presents Data on Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) in Virologically Suppressed Adults, Including Those With Pre-Existing NRTI Resistance
Gilead Sciences, Inc. announced data from two studies evaluating the resistance profile of Biktarvy® in virologically suppressed adults switching from dolutegravir/abacavir/lamivudine or a boosted protease inhibitor-based regimen for the treatment of HIV-1.
Glenmark Pharmaceuticals’ new innovation business has its chief executive officer. Alessandro Riva, head of oncology therapeutics and cell therapy at Gilead Sciences will take over the reins of the new innovation company as its CEO on April 2. Riva is the first named executive of the new company.
Gilead Sciences, Inc. announced that Alessandro Riva, MD, Executive Vice President, Oncology Therapeutics, has decided to leave the company to pursue another opportunity.
Gilead Sciences, Inc. announced that Robin L. Washington, Gilead’s Executive Vice President and Chief Financial Officer and John McHutchison, AO, MD, Gilead’s Chief Scientific Officer and Head of Research & Development, will participate in a fireside chat at the Barclays Global Healthcare Conference in Miami on Tuesday, March 12 at 10:45 a.m. Eastern Time.
Evaluate recently published the Vantage Pharma, Biotech and Medtech 2018 in review report. The annual report offers insights into the previous year’s activities in biopharma and the medical device industry.
Gilead Sciences Launches Age Positively Initiative to Address Unique Challenges of Aging Population Living with HIV
Initiative to Provide $17.6 Million to 30 U.S. Organizations to Elevate the Work of Community Groups and Provide Support Needed to Strengthen Care for People Aging with HIV
Superior Court of California, County of Los Angeles rejects all but one of Gilead’s arguments in demurrer seeking to have personal injury cases over its promotion of TDF-based HIV/AIDS medications that cause permanent damage to kidneys and bones dismissed.
Gilead Sciences announced that its selonsertib to treat compensated cirrhosis from nonalcoholic steatohepatitis (NASH) did not meet its primary endpoint in the STELLAR-4 Phase III trial. Given Gilead’s expertise in liver diseases, the setback is particularly discouraging.
Gilead Announces Topline Data From Phase 3 STELLAR-4 Study of Selonsertib in Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
Gilead Sciences, Inc. announced that STELLAR-4, a Phase 3, placebo-controlled study evaluating the safety and efficacy of selonsertib, oral inhibitor of apoptosis signal-regulating kinase 1, did not meet the pre-specified week 48 primary endpoint of a ≥ 1-stage histologic improvement in fibrosis without worsening of NASH.
Gilead Sciences reported earnings per share profits for the fourth quarter of $1.44 per share, below analysts’ expectations of $1.70.
IDEA Pharma recently published its “Pharmaceutical Innovation Index 2018.” This report ranks biopharma companies on their ability to bring products from Phase I/II to market and then successfully commercialize them. They used a variety of sources, including company websites, third-party instituti...
Gilead Sciences, Inc. announced its results of operations for the fourth quarter and full year 2018.
Gilead Sciences, Inc. announced that the company’s Board of Directors has declared an increase of 11% in the company’s quarterly cash dividend, beginning in the first quarter of 2019.
The funds raised will be used to advance the company’s lead product into Phase II clinical trials, expand its Phase I pipeline, and scale-up its manufacturing capacity.
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, and adoptive cell therapies1, today announced the closing of its immuno-oncology (I-O) partnership deal with Gilead Sciences, Inc. (NASDAQ: GILD), focused on the development and commercialization of up to five novel immuno-oncology therapies.
Gilead Sciences to Release Fourth Quarter and Full Year 2018 Financial Results on Monday, February 4, 2019
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2018 financial results will be released on Monday, February 4, after the market closes.
Nonalcoholic steatohepatitis (NASH) is prevalent in the U.S. and developing countries, but under that name, is largely unknown to the general public. NASH is a liver disease similar to cirrhosis, but which occurs in people who drink little or no alcohol.